These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
549 related articles for article (PubMed ID: 29649617)
1. Reversal of T Cell Exhaustion by the First Donor Lymphocyte Infusion Is Associated with the Persistently Effective Antileukemic Responses in Patients with Relapsed AML after Allo-HSCT. Liu L; Chang YJ; Xu LP; Zhang XH; Wang Y; Liu KY; Huang XJ Biol Blood Marrow Transplant; 2018 Jul; 24(7):1350-1359. PubMed ID: 29649617 [TBL] [Abstract][Full Text] [Related]
2. Donor lymphocyte infusion for the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. Takami A; Yano S; Yokoyama H; Kuwatsuka Y; Yamaguchi T; Kanda Y; Morishima Y; Fukuda T; Miyazaki Y; Nakamae H; Tanaka J; Atsuta Y; Kanamori H Biol Blood Marrow Transplant; 2014 Nov; 20(11):1785-90. PubMed ID: 25034960 [TBL] [Abstract][Full Text] [Related]
3. Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: superior outcomes compared with chemotherapy alone and an analysis of prognostic factors. Yan CH; Wang JZ; Liu DH; Xu LP; Chen H; Liu KY; Huang XJ Eur J Haematol; 2013 Oct; 91(4):304-14. PubMed ID: 23837640 [TBL] [Abstract][Full Text] [Related]
4. Sequential intensified conditioning followed by prophylactic DLI could reduce relapse of refractory acute leukemia after allo-HSCT. Xuan L; Fan Z; Zhang Y; Zhou H; Huang F; Dai M; Nie D; Lin D; Xu N; Guo X; Jiang Q; Sun J; Xiao Y; Liu Q Oncotarget; 2016 May; 7(22):32579-91. PubMed ID: 27081039 [TBL] [Abstract][Full Text] [Related]
5. Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse. Kharfan-Dabaja MA; Labopin M; Polge E; Nishihori T; Bazarbachi A; Finke J; Stadler M; Ehninger G; Lioure B; Schaap N; Afanasyev B; Yeshurun M; Isaksson C; Maertens J; Chalandon Y; Schmid C; Nagler A; Mohty M JAMA Oncol; 2018 Sep; 4(9):1245-1253. PubMed ID: 30003233 [TBL] [Abstract][Full Text] [Related]
6. T cell exhaustion characterized by compromised MHC class I and II restricted cytotoxic activity associates with acute B lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation. Liu L; Chang YJ; Xu LP; Zhang XH; Wang Y; Liu KY; Huang XJ Clin Immunol; 2018 May; 190():32-40. PubMed ID: 29477343 [TBL] [Abstract][Full Text] [Related]
7. Spectral flow cytometry cluster analysis of therapeutic donor lymphocyte infusions identifies T cell subsets associated with outcome in patients with AML relapse. Odak I; Sikora R; Riemann L; Bayir LM; Beck M; Drenker M; Xiao Y; Schneider J; Dammann E; Stadler M; Eder M; Ganser A; Förster R; Koenecke C; Schultze-Florey CR Front Immunol; 2022; 13():999163. PubMed ID: 36275657 [TBL] [Abstract][Full Text] [Related]
9. Chemotherapy versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplant. Motabi IH; Ghobadi A; Liu J; Schroeder M; Abboud CN; Cashen AF; Stockler-Goldstein KE; Uy GL; Vij R; Westervelt P; DiPersio JF Biol Blood Marrow Transplant; 2016 Jul; 22(7):1324-1329. PubMed ID: 27026249 [TBL] [Abstract][Full Text] [Related]
10. Interferon-α Is Effective for Treatment of Minimal Residual Disease in Patients with t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Registry Study. Mo XD; Wang Y; Zhang XH; Xu LP; Yan CH; Chen H; Chen YH; Qin YZ; Liu KY; Huang XJ Oncologist; 2018 Nov; 23(11):1349-1357. PubMed ID: 30076280 [TBL] [Abstract][Full Text] [Related]
11. CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Cui Q; Qian C; Xu N; Kang L; Dai H; Cui W; Song B; Yin J; Li Z; Zhu X; Qu C; Liu T; Shen W; Zhu M; Yu L; Wu D; Tang X J Hematol Oncol; 2021 May; 14(1):82. PubMed ID: 34034795 [TBL] [Abstract][Full Text] [Related]
12. Case report: Donor-derived CLL-1 chimeric antigen receptor T-cell therapy for relapsed/refractory acute myeloid leukemia bridging to allogeneic hematopoietic stem cell transplantation after remission. Miao X; Shuai Y; Han Y; Zhang N; Liu Y; Yao H; Wang X; He G; Chen D; Fan F; Chang AH; Su Y; Yi H Front Immunol; 2024; 15():1389227. PubMed ID: 38803489 [TBL] [Abstract][Full Text] [Related]
13. Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease-Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Refractory/Relapsed Acute Leukemia. Yan CH; Liu QF; Wu DP; Zhang X; Xu LP; Zhang XH; Wang Y; Huang H; Bai H; Huang F; Ma X; Huang XJ Biol Blood Marrow Transplant; 2017 Aug; 23(8):1311-1319. PubMed ID: 28483716 [TBL] [Abstract][Full Text] [Related]
14. Interferon-α: A Potentially Effective Treatment for Minimal Residual Disease in Acute Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation. Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ Biol Blood Marrow Transplant; 2015 Nov; 21(11):1939-47. PubMed ID: 26116088 [TBL] [Abstract][Full Text] [Related]
15. Donor Lymphocyte Infusions Used to Treat Mixed-Chimeric and High-Risk Patient Populations in the Relapsed and Nonrelapsed Settings after Allogeneic Transplantation for Hematologic Malignancies Are Associated with High Five-Year Survival if Persistent Full Donor Chimerism Is Obtained or Maintained. Caldemeyer LE; Akard LP; Edwards JR; Tandra A; Wagenknecht DR; Dugan MJ Biol Blood Marrow Transplant; 2017 Nov; 23(11):1989-1997. PubMed ID: 28712934 [TBL] [Abstract][Full Text] [Related]
16. Extramedullary relapse of acute leukemia after allogeneic hematopoietic stem cell transplantation: different characteristics between acute myelogenous leukemia and acute lymphoblastic leukemia. Ge L; Ye F; Mao X; Chen J; Sun A; Zhu X; Qiu H; Jin Z; Miao M; Fu C; Ma X; Chen F; Xue S; Ruan C; Wu D; Tang X Biol Blood Marrow Transplant; 2014 Jul; 20(7):1040-7. PubMed ID: 24704575 [TBL] [Abstract][Full Text] [Related]
17. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. Schmid C; Labopin M; Nagler A; Bornhäuser M; Finke J; Fassas A; Volin L; Gürman G; Maertens J; Bordigoni P; Holler E; Ehninger G; Polge E; Gorin NC; Kolb HJ; Rocha V; J Clin Oncol; 2007 Nov; 25(31):4938-45. PubMed ID: 17909197 [TBL] [Abstract][Full Text] [Related]
18. Donor Lymphocyte Infusion Is a Feasible Way to Improve Survival in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Who Relapse after Allogeneic Stem Cell Transplantation. Minculescu L; Reekie J; Petersen SL; Kornblit BT; Schjoedt I; Andersen NS; Andersen LP; Fischer-Nielsen A; Haastrup EK; Friis LS; Sengelov H Acta Haematol; 2024; 147(3):325-332. PubMed ID: 37827141 [TBL] [Abstract][Full Text] [Related]
19. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group. Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985 [TBL] [Abstract][Full Text] [Related]
20. Haematologic malignancies with unfavourable gene mutations benefit from donor lymphocyte infusion with/without decitabine for prophylaxis of relapse after allogeneic HSCT: A pilot study. Zhang R; Wang L; Chen P; Gao X; Wang S; Li F; Dou L; Gao C; Li Y; Liu D Cancer Med; 2021 May; 10(10):3165-3176. PubMed ID: 33932107 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]